Cell Bank Resilience as Biomanufacturing Becomes Critical Infrastructure
Cell bank resilience entered the policy conversation this fall. On September 24, 2026, lawmakers introduced the Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act (H.R. 10569). The bill would direct the Cybersecurity and Infrastructure Security Agency to protect biomanufacturing infrastructure. Consequently, buyers are asking sharper questions about the biological starting material behind a program.
Why Cell Bank Resilience Draws Policy Attention
A cell bank is not a commodity input. Instead, it is the one material a program cannot simply reorder. Therefore its identity, documentation, and storage conditions carry unusual weight. Meanwhile, the bill frames biomanufacturing capacity as a national asset rather than a routine supply line.
For diagnostic and reagent manufacturers, that framing lands close to home, because continuity of a cell line means continuity of product supply. Legislation stays a proposal until Congress acts, so treat the bill as direction rather than rule. The full text sits on GovInfo, and your regulatory team can confirm specifics there.
What Cell Bank Resilience Requires at the Bench
Three practices make a bank defensible. First, confirm identity. Our cell banking services include STR and whole-genome sequencing, plus mycoplasma and sterility testing. Next, prove viability, because every bank includes a test vial thaw. Finally, control the storage environment.
Vials freeze first in a controlled-rate -80 °C step, then transfer to vapor phase liquid nitrogen. We monitor those dewars around the clock, with backup generators and off-site disaster recovery. Documentation then closes the loop, since each project carries batch records and a Certificate of Analysis under our ISO 9001:2015 quality system.
Passage history deserves equal attention. Expression and growth characteristics drift as passage number climbs, so a master bank drawn early anchors every later comparison. Additionally, genetic stability assessment and expression validation give that bank a measured baseline rather than an assumption.
Evaluating a Partner on Cell Bank Resilience
Continuity is the criterion worth testing. Cell Culture Company has run mammalian and insect cell culture from one Shoreview, Minnesota facility since 1983. As a result, the same US-based team stays with a program from gene sequence through cell line development, protein production, and purification.
Scale flexibility matters just as much. We bank anywhere from 5 vials to thousands of vials per lot. Additionally, we expand cultures from shaker flasks up to 200 L suspension, or 75,000 cm² adherent per batch. A program can therefore move up or down that range without changing vendors.
Frequently Asked Questions
What does cell bank resilience mean in practice?
It means documented identity, confirmed viability, and controlled storage. Together, those records let a team reconstruct exactly what a vial contains.
How many vials belong in a master cell bank?
Needs vary with program length and batch cadence. We prepare banks from as few as 5 vials up to thousands of vials per lot. However, banking early and at low passage protects every later comparison.
